MGTD has always maintained a tradition of developing
successful partnerships with reputed parties all over the world, in addition
to its own development projects. MGTD welcomes the US, Japanese
and European companies to partner with us and cash in on a mutual beneficial and fruitful
business opportunities and forges broadpartnerships to develop, register
and commercialize their products in our health ministry (Out- Lenience). Rising the
confidence in our financial management and our capital resource encourage us to press ahead
on a normalization path that consequently has helped us drive up yields in the mutual
business. Our Investors no longer need to take on as much risk to generate enough return on
their fiscal budgets. Our Investors have piled into safest business in our organization for
search of higher their yields and their remarkable dividends.
We are actively evaluating potential (Out-licensing) opportunities for Generic and innovative
products, where significant unmet medical need exists or in subset patient populations where
the compound may have significant promise.